Form 4: Zentalis Pharmaceuticals Director Scott Myers Receives Equity Grant

Zentalis Pharmaceuticals, Inc. Director Scott Dunseth Myers was granted 57,603 restricted stock units as part of the company's non-employee director compensation program.

Summary

• Scott Dunseth Myers, a Director of Zentalis Pharmaceuticals, Inc. (ZNTL), acquired 57,603 shares of common stock.
• This acquisition occurred on June 17, 2025, at a price of $0 per share.
• The shares represent restricted stock units (RSUs) granted under the Issuer's Non-Employee Director Compensation Program.
• Each RSU represents a contingent right to receive one share of common stock.
• These RSUs are scheduled to vest on the earlier of June 17, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Mr. Myers' continued service on the Issuer's Board of Directors through the vesting date.
• Following this transaction, Scott Dunseth Myers beneficially owns a total of 338,795 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial news. It's a standard, expected event.

Positives

• The grant of restricted stock units to Director Scott Dunseth Myers aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.
• This is a standard component of non-employee director compensation, indicating a structured approach to governance and incentivization.

Risks

• The vesting of the restricted stock units is subject to the reporting person's continued service on the Issuer's Board of Directors, meaning the shares could be forfeited if service ceases before the vesting date.

Future Outlook

This filing pertains to a specific compensation event and does not provide a general future outlook for the company's operations or financial performance.

Industry Context

The granting of restricted stock units to non-employee directors is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, as a means to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of non-employee director compensation is a widely accepted and standard practice in corporate governance across industries, including pharmaceuticals.
• Companies like Pfizer, Merck, and Johnson & Johnson commonly utilize equity-based compensation, such as RSUs or stock options, for their non-executive directors to align their interests with long-term shareholder value.
• The specific amount of RSUs granted (57,603) and the vesting schedule (one year or next annual meeting) are typical for such programs, reflecting a balance between immediate incentive and long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Scott Dunseth Myers, a Director of Zentalis Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making focused on shareholder value.

Next Steps

• Vesting of the 57,603 restricted stock units on the earlier of June 17, 2026, or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Zentalis Pharmaceuticals, ZNTL, SEC Form 4, insider transaction, director compensation, restricted stock units, RSU grant, equity compensation, corporate governance, Scott Dunseth Myers